REPOSITIONING INTELLIGENCE — EVIDENCE REPORT
============================================
Generated: Nov 12, 2026, 11:53 PM UTC

DISCLAIMER: This report is for research and informational use only.
It is NOT medical advice, diagnosis, or treatment guidance.

DRUG–DISEASE PAIRING
--------------------
Drug:     Aspirin
Disease:  Cardiovascular Disease
Target:   Cyclooxygenase-1

EVIDENCE GRADE: Approved
Confidence Score: 92%
Evidence Level: Level 1 (meta-analysis of RCTs)
Trial Phase: Multiple Phase III trials

MECHANISM
---------
Irreversible COX-1 inhibition reduces thromboxane A2-mediated platelet aggregation.

OUTCOMES
--------
Reduced major vascular events in secondary prevention; primary prevention benefit-risk varies by age.

AI SUMMARY (generated March 15, 2026)
-----------
Low-dose aspirin has Level 1 evidence for secondary cardiovascular prevention. Primary prevention guidelines have narrowed due to bleeding risk in lower-risk populations (ASPREE, ARRIVE trials).

KNOWN RISKS
-----------
• GI bleeding and ulceration
• Hemorrhagic stroke (low absolute risk)
• Reye syndrome in children
• Allergy (aspirin-exacerbated respiratory disease)

CITATIONS
---------
[PUBMED] 12102808: Antithrombotic Trialists' Collaboration meta-analysis
  https://pubmed.ncbi.nlm.nih.gov/12102808/

[CLINICALTRIALS] NCT00139815: ASPREE trial
  https://clinicaltrials.gov/study/NCT00139815

PUBMED IDs: 12102808
CLINICAL TRIAL IDs: NCT00139815

LAST VERIFIED: June 26, 2026
LAST UPDATED:  June 26, 2026
REVIEW STAGE:  published

---
Repositioning Intelligence Platform · Research Mode